Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (8168)	1/2/1999 6:48:00 PM
From: Robert K.	Read Replies (2) \| Respond to of 17367

From company website........"If we wait for product approvals, large pharmaceutical company collaborations for NEUPREX® or other major milestones, we run a risk that the "fair value" of the assets will become significantly higher and that resulting capital gains taxes will make the reorganization prohibitively expensive." End Note the 3 items mentioned 1. product approvals 2. large company collaborations for neuprex 3. major milestones (like maybe hu1124) Funny they should mention those. Guess we dont have to "worry" about those three anymore from a timing aspect. :-) Yeah, I think news is gonna come. Lots of it. Just hope its of the good variety. All IMO as always.